Search Result

Results for "

GSK-3 inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GSK-3 (114) AAK1 (1) Akt (2) AMPK (1) Amyloid-β (3) Antibiotic (5) Apoptosis (12) Aurora Kinase (5) Autophagy (13) Bacterial (5) Beta-secretase (1) c-Myc (1) Calcium Channel (2) CDK (29) CFTR (1) Cholinesterase (ChE) (5) DYRK (6) ERK (1) FGFR (2) Glucosidase (1) HDAC (1) HIV (1) HSV (3) IAP (1) IKK (2) Integrin (1) Isotope-Labeled Compounds (2) JAK (4) JNK (2) LIM Kinase (LIMK) (1) Lipoxygenase (1) LRRK2 (1) MAP3K (1) MEK (2) Microtubule/Tubulin (1) Mitophagy (3) Organoid (5) p38 MAPK (2) Parasite (2) PDK-1 (2) Phosphatase (1) Phosphodiesterase (PDE) (2) Phospholipase (1) PI3K (2) Pim (2) PKC (8) PROTACs (1) Proton Pump (2) RANKL/RANK (1) Ribosomal S6 Kinase (RSK) (1) ROS Kinase (1) Src (2) Syk (1) Tau Protein (3) TGF-β Receptor (1) TRP Channel (1) VEGFR (2) Wnt (6) β-catenin (8)
By Research Areas:	Cancer (75) Cardiovascular Disease (4) Infection (11) Inflammation/Immunology (16) Metabolic Disease (29) Neurological Disease (56)

By Targets:

GSK-3 (114)

AAK1 (1)

Akt (2)

AMPK (1)

Amyloid-β (3)

Antibiotic (5)

Apoptosis (12)

Aurora Kinase (5)

Autophagy (13)

Bacterial (5)

Beta-secretase (1)

c-Myc (1)

Calcium Channel (2)

CDK (29)

CFTR (1)

Cholinesterase (ChE) (5)

DYRK (6)

ERK (1)

FGFR (2)

Glucosidase (1)

HDAC (1)

HIV (1)

HSV (3)

IAP (1)

IKK (2)

Integrin (1)

Isotope-Labeled Compounds (2)

JAK (4)

JNK (2)

LIM Kinase (LIMK) (1)

Lipoxygenase (1)

LRRK2 (1)

MAP3K (1)

MEK (2)

Microtubule/Tubulin (1)

Mitophagy (3)

Organoid (5)

p38 MAPK (2)

Parasite (2)

PDK-1 (2)

Phosphatase (1)

Phosphodiesterase (PDE) (2)

Phospholipase (1)

PI3K (2)

Pim (2)

PKC (8)

PROTACs (1)

Proton Pump (2)

RANKL/RANK (1)

Ribosomal S6 Kinase (RSK) (1)

ROS Kinase (1)

Src (2)

Syk (1)

Tau Protein (3)

TGF-β Receptor (1)

TRP Channel (1)

VEGFR (2)

Wnt (6)

β-catenin (8)

By Research Areas:

Cancer (75)

Cardiovascular Disease (4)

Infection (11)

Inflammation/Immunology (16)

Metabolic Disease (29)

Neurological Disease (56)

149

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: GSK-3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-154851

GSK-3 inhibitor 3	GSK-3 CDK Tau Protein	Neurological Disease
GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of *GSK-3, with IC₅₀s of 0.35 nM and 0.25 nM for GSK-3α and GSK-3β, respectively. GSK-3* inhibitor 3 lowers levels of tau protein phosphorylation at S396 in a triple-transgenic mouse Alzheimer’s disease model, with IC₅₀ of 10 nM. GSK-3 inhibitor 3 can be used for neurological disease research .

HY-30236

5-Bromoindole

Others Cancer

5-Bromoindole is a chemical intermediate that can be used for the synthesis of GSK-3 inhibitors and anti-cancer agents .
HY-112392

GSK-3 Inhibitor XIII

GSK-3 Cancer

GSK-3 Inhibitor XIII is a potent and ATP-competitive GSK-3 inhibitor with a K_i of 24 nM .

5-Bromoindole	Others	Cancer
5-Bromoindole is a chemical intermediate that can be used for the synthesis of GSK-3 inhibitors and anti-cancer agents .

GSK-3 Inhibitor XIII	GSK-3	Cancer
GSK-3 Inhibitor XIII is a potent and ATP-competitive *GSK-3* inhibitor with a K_i of 24 nM .

HY-154852

GSK-3 inhibitor 4	GSK-3 CDK	Neurological Disease
GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of *GSK-3, CDK2, and CDK5, with IC₅₀* values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies .

HY-155989

GSK3-IN-4

GSK-3 Neurological Disease

GSK3-IN-4 (compound 0715) is a potent GSK3 inhibitor. GSK3-IN-4 can be used for psychiatric disorder research .
HY-Q48328

GSK3-IN-1

GSK-3 Metabolic Disease

GSK3-IN-1 (compound 11) is a GSK-3 inhibitor with an IC₅₀ value of 12 μM. GSK3-IN-1 can be used in the research of diabetes .
HY-148329

GSK3-IN-2

GSK-3 Metabolic Disease

GSK3-IN-2 (compound 8) is a potent GSK3 inhibitor .

GSK3-IN-4	GSK-3	Neurological Disease
GSK3-IN-4 (compound 0715) is a potent *GSK3* inhibitor. GSK3-IN-4 can be used for psychiatric disorder research .

GSK3-IN-1	GSK-3	Metabolic Disease
GSK3-IN-1 (compound 11) is a *GSK-3* inhibitor with an IC₅₀ value of 12 μM. GSK3-IN-1 can be used in the research of diabetes .

GSK3-IN-2	GSK-3	Metabolic Disease
GSK3-IN-2 (compound 8) is a potent *GSK3* inhibitor .

HY-153089

GSK3-IN-3 1 Publications Verification	GSK-3 Mitophagy	Neurological Disease
GSK3-IN-3 is a mitophagy inducer, inducing Parkin-dependent mitophagy. GSK3-IN-3 is also a *GSK-3* inhibitor with an IC₅₀ value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA .

HY-107528

FRATtide	β-catenin GSK-3	Cancer
FRATtide is a peptide derived from the GSK-3 binding protein that inhibits the phosphorylation of Axin and β-catenin. FRATtide inhibits *GSK-3* binding to Axin .

HY-13973A

GSK-3 inhibitor 1 1 Publications Verification	GSK-3	Metabolic Disease
GSK-3 inhibitor 1 (compound core 3) is a *GSK-3* inhibitor that induces stem/progenitor cell self-renewal (e.g. induces stem/progenitor cell proliferation while maintaining the ability to differentiate into tissue cells in the progeny) .

HY-107531

A 1070722	GSK-3	Cancer
A 1070722 is a potent and selective glycogen synthase kinase 3 (GSK-3) inhibitor, with a K_i of 0.6 nM for both GSK-3α and GSK-3β. A 1070722 can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for the quantification of GSK-3 in brain .

HY-12012

SB 216763 25+ Cited Publications	GSK-3 Autophagy	Neurological Disease Cancer
SB 216763 is potent, selective and ATP-competitive *GSK-3* inhibitor with IC₅₀s of 34.3 nM for both GSK-3α and GSK-3β.

HY-16294

LY2090314 10+ Cited Publications	GSK-3	Cancer
LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC₅₀ values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

HY-15761

AZD2858 5+ Cited Publications	GSK-3	Neurological Disease
AZD2858 is a potent, orally active *GSK-3* inhibitor, with IC₅₀s of 0.9 and 5 nM for *GSK-3α* and *GSK-3β*, respectively, used in the research of fracture healing.

HY-107530

3F8	GSK-3	Cardiovascular Disease Metabolic Disease Cancer
3F8 is a potent and selective *GSK-3β* inhibitor that could be useful as new reagent and potential therapeutic candidate for GSK3 related diseases .

HY-15356

BIO-acetoxime 1 Publications Verification BIA	GSK-3 Apoptosis HSV	Infection Neurological Disease Inflammation/Immunology
BIO-acetoxime (BIA) is a potent and selective *GSK-3* inhibitor, with IC₅₀s of both 10 nM for GSK-3α/β. BIO-acetoxime has anticonvulsant and anti-infection activity.

HY-14872

Tideglusib 5 Publications Verification NP031112	GSK-3	Neurological Disease
Tideglusib (NP031112) is an irreversible *GSK-3* inhibitor with IC₅₀s of 5 nM and 60 nM for GSK-3β ^WT (1 h preincubation) and GSK-3β ^C199A (1 h preincubation), respectively.

HY-111055

BIP-135	GSK-3	Neurological Disease
BIP-135 is a potent and selective ATP-competitive *GSK-3* inhibitor, with IC₅₀s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect .

HY-134557

GS87	GSK-3	Cancer
GS87 is a highly specific and potent *GSK3* inhibitor with IC₅₀s of 415nM and 521nM for GSK3α and GSK3β, respectively. GS87 induces differentiation of acute myeloid leukemia (AML) cell lines by effectively activating GSK3-dependent signaling components including MAPK signaling. GS87 modulates key GSK3 target proteins involved in cell proliferation and differentiation more effectively than Lithium and SB415285 (SB). GS87 has the potential for acting as a differentiation agent for non-promyelocytic AML research .

HY-13862

AZD1080 5 Publications Verification	GSK-3	Neurological Disease
AZD1080 is a potent and selective *GSK3* inhibitor. AZD1080 inhibits recombinant human *GSK3α* and *GSK3β* with pK_i (IC₅₀) of 8.2 (6.9 nM) and 7.5 (31 nM), respectively.

HY-13076

CHIR-98014 3 Publications Verification	GSK-3	Metabolic Disease
CHIR-98014 is a potent, cell-permeable *GSK-3* inhibitor with IC₅₀s of 0.65 and 0.58 nM for *GSK-3α* and *GSK-3β*, respectively; it shows less potent activities against cdc2 and erk2.

HY-122026

PF-04802367 PF-367	GSK-3	Neurological Disease
PF-04802367 (PF-367) is a highly selective *GSK-3* inhibitor with an IC₅₀ of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367 shows desirable central nervous system (CNS) properties and potency. PF-04802367 is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and *GSK-3β) with IC₅₀* values of 10.0 and 9.0 nM in mobility shift assays, respectively .

HY-128879A

VP3.15 dihydrobromide 1 Publications Verification	Phosphodiesterase (PDE) GSK-3	Neurological Disease
VP3.15 dihydrobromide is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC₅₀s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 dihydrobromide has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS) .

HY-128879

VP3.15	Phosphodiesterase (PDE) GSK-3	Neurological Disease
VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC₅₀s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS) .

HY-156032

PIMPC	GSK-3	Neurological Disease
PIMPC is a compound with antioxidant and metal-chelating properties. PIMPC is a novel inhibitor of glycogen synthase kinase 3 (GSK-3). PIMPC has potential anti-Alzheimer's disease effect .

HY-12074

Cazpaullone	GSK-3	Metabolic Disease
Cazpaullone is a glycogen synthase kinase-3 (GSK-3) inhibitor. Cazpaullone can activate pancreatic beta cell protection and replication. Cazpaullone can be used for the research of diabetes .

HY-107815

CHIR 98024

GSK-3 Neurological Disease

CHIR 98024 (Compound L) is a glycogen synthase kinase 3 (GSK3) inhibitor with an EC₅₀ of 0.2566 μM .

CHIR 98024	GSK-3	Neurological Disease
CHIR 98024 (Compound L) is a glycogen synthase kinase 3 (GSK3) inhibitor with an EC₅₀ of 0.2566 μM .

HY-124607

(R)-BRD3731	GSK-3	Neurological Disease
(R)-BRD3731 is a *GSK3* inhibitor extracted from patent US20160375006A1, compound example 273, has IC₅₀s of 1.05 and 6.7 μM for *GSK3β* and *GSK3α*, respectively .

HY-126125

CHIR-98023	GSK-3	Neurological Disease Metabolic Disease
CHIR-98023 is a potent, selective and reversible inhibitor of *GSK3, with IC₅₀s of 10 nM and 6.7 nM for GSK3α* and *GSK3β*, respectively. CHIR-98023 can improve insulin action and glucose metabolism .

HY-134622

GSK-3/CDK5/CDK2-IN-1	CDK GSK-3	Neurological Disease Cancer
GSK-3/CDK5/CDK2-IN-1, an imidazole derivative, is an inhibitor of cdk5, cdk2, and *GSK-3* extracted from patent WO2002010141A1, example 9a. GSK-3/CDK5/CDK2-IN-1 can be used for the research of cancer, and neurodegenerative diseases .

HY-137472

SAR502250	GSK-3	Neurological Disease
SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of *GSK3, with an IC₅₀* of 12 nM for human GSK-3β. SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s disease (AD) .

HY-13867

Bisindolylmaleimide I 30+ Cited Publications GF109203X; Go 6850	PKC GSK-3	Metabolic Disease Cancer
Bisindolylmaleimide I (GF109203X) is a cell-permeable and reversible PKC inhibitor (IC₅₀ of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I is also a *GSK-3* inhibitor .

HY-13867A

Bisindolylmaleimide I hydrochloride 30+ Cited Publications GF109203X hydrochloride; Go 6850 hydrochloride	PKC GSK-3	Metabolic Disease Cancer
Bisindolylmaleimide I (GF109203X) hydrochloride is a cell-permeable and reversible PKC inhibitor (IC₅₀ of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I hydrochloride is also a *GSK-3* inhibitor .

HY-100950

ABC1183
ABC1183 is an orally active selective dual *GSK3* and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC₅₀ values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities .

HY-114903

(E/Z)-BIO-acetoxime GSK-3 Inhibitor X	GSK-3 CDK	Neurological Disease Metabolic Disease Cancer
(E/Z)-BIO-acetoxime (GSK-3 Inhibitor X) is a potent and selective *GSK-3α/β* inhibitor, with an IC₅₀ of 10 nM. (E/Z)-BIO-acetoxime shows more than 200-flod selectivity over CDK5/p25, CDK2/cyclin A and CDK1/cyclin B (IC₅₀=2.4, 4.3, 63 μM) .

HY-10182

Laduviglusib 140+ Cited Publications CHIR-99021; CT99021	Organoid GSK-3 Wnt β-catenin Autophagy	Metabolic Disease Cancer
Laduviglusib (CHIR-99021) is a potent, selective and orally active *GSK-3α/β* inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for *GSK-3* over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy .

HY-10182B

Laduviglusib trihydrochloride 140+ Cited Publications CHIR-99021 trihydrochloride; CT99021 trihydrochloride	Organoid GSK-3 Wnt β-catenin Autophagy	Cancer
Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective *GSK-3α/β* inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for *GSK-3* over CDC2, ERK2 and other protein kinases. Laduviglusib trihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib trihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib trihydrochloride induces autophagy .

HY-10182A

Laduviglusib monohydrochloride 140+ Cited Publications CHIR-99021 monohydrochloride; CT99021 monohydrochloride	Organoid GSK-3 Wnt β-catenin Autophagy	Cancer
Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective *GSK-3α/β* inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for *GSK-3* over CDC2, ERK2 and other protein kinases. Laduviglusib monohydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib monohydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib monohydrochloride induces autophagy .

HY-151575

PfGSK3/PfPK6-IN-2	GSK-3	Infection
PfGSK3/PfPK6-IN-2 is a potent dual PfGSK3/PfPK6 (Plasmodium falciparum GSK3/PK6) inhibitor (IC₅₀: 172 nM and 11 nM respectively). PfGSK3/PfPK6-IN-2 can be used in the research of Malaria .

HY-P1173

L803-mts Myristoylated L 803; GSK-3β Inhibitor XIII	GSK-3 Amyloid-β	Neurological Disease
L803-mts (Myristoylated L 803) is a selective and substrate-competitive *GSK-3* peptide inhibitor (IC₅₀: 40 μM). L803-mts also reduces Aβ deposits and ameliorates cognitive deficits in 5XFAD mice. L803-mts shows antidepressive effect in the forced swimming test .

HY-N3542

Carpachromene	Glucosidase	Cancer
Carpachromene is a potent α-glucosidase enzyme inhibitor. Carpachromene ameliorates insulin resistance in HepG2 cells via modulating IR/IRS1/PI3k/Akt/GSK3/FoxO1 pathway .

HY-112336

Aloisine RP106	CDK GSK-3	Neurological Disease
Aloisine RP106 (compound 38) is a potent inhibitor of Cdk1/cyclin B, Cdk5/p25, and *GSK3* with IC₅₀s of 0.70µM, 1.5µM, 0.92 µM, respectively .

HY-121629

PS210	PDK-1	Cancer
PS210 is a potent and selective PDK1 activator with a K_d of 3 μM and targets the PIF-binding pocket of PDK1. PS210 is inactive against other protein kinases, including PDK1 downstream signaling components such as S6K, PKB/Akt or GSK3. In cells, the prodrug of PS210 (PS423) acts as a substrate-selective inhibitor of PDK1, inhibiting the phosphorylation and activation of S6K .

HY-155723

Leucettinib-92	CDK DYRK	Others
Leucettinib-92 (compound 92) is an inhibitor of DYRK/CLK kinase, The IC₅₀s are 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM (CLK3), 124 nM (DYRK1A), 204 nM (DYRK1B), 0.16 μM (DYRK2), respectively. 1.0 μM (DYRK3), 0.52 μM (DYRK4), 2.78 μM (GSK3) .

HY-141685

3-Methylthienyl-carbonyl-JNJ-7706621	CDK GSK-3 VEGFR FGFR	Cancer
3-Methylthienyl-carbonyl-JNJ-7706621 is a potent and selective inhibitor of cyclin-dependent kinase (CDK), with IC₅₀s of 6.4 nM and 2 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. 3-Methylthienyl-carbonyl-JNJ-7706621 also shows potent inhibition of *GSK-3* (IC₅₀=0.041 μM) and modest potency against CDK4, VEGF-R2, and FGF-R2 (IC₅₀=0.11, 0.13, 0.22 μM, respectively). 3-Methylthienyl-carbonyl-JNJ-7706621 can be used for the research of cancer .

HY-148133

GSK-3β inhibitor 12	GSK-3	Neurological Disease
GSK-3β inhibitor 12 (compound 15) is an inhibitor of *GSK-3β. GSK-3β inhibitor* 12 inhibits 49.11% and 37.11% activity of 25 μM and 50 μM GSK-3β, respectively. GSK-3β inhibitor 12 can be used for the research of neurodegenerative diseases .

HY-149542

GSK-3β inhibitor 15	Tau Protein Apoptosis GSK-3	Neurological Disease
GSK-3β inhibitor 15 (Compound 54) is a *GSK-3β* inhibitor (IC₅₀: 3.4 nM). GSK-3β inhibitor 15 inhibits Aβ_1-42-induced GSK-3β and tau protein phosphorylation. GSK-3β inhibitor 15 inhibits LPS-induced iNOS expression. GSK-3β inhibitor 15 has neuroprotective effects on Aβ_1-42-induced neurotoxicity. GSK-3β inhibitor 15 can be used for research of Alzheimer’s disease (AD) .

HY-149054

GSK-3β inhibitor 13	GSK-3 Tau Protein AAK1 Pim PKC	Neurological Disease
GSK-3β inhibitor 13 (compound 47) is an orally active and potent *GSK-3β* inhibitor with blood-brain permeability. GSK-3β inhibitor 13 inhibits *GSK-3β* and *GSK-3α* with IC₅₀s of 0.73 nM and 0.35 nM, respectively. GSK-3β inhibitor 13 significantly decreases the phosphorylation of tau (IC₅₀=58 nM), which leads the formation of the neurofibrillary tangles associated with Alzheimer's disease .

HY-130795

GSK-3β inhibitor 2 1 Publications Verification	GSK-3	Neurological Disease
GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active *GSK-3β* inhibitor with an IC₅₀ of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease .

HY-147134

GSK-3β inhibitor 10	GSK-3	Neurological Disease
GSK-3β inhibitor 10 (compound 14a) is a highly potent *GSK-3β* inhibitor with an IC₅₀ value of 80.5 nM. GSK-3β inhibitor 10 can be used for researching Alzheimer’s disease .

Cat. No.	Product Name

HY-L020

Wnt/Hedgehog/Notch Compound Library

358 compounds

The developmental proteins Hedgehog, Notch and Wnt are key regulators of cell fate, proliferation, migration and differentiation in several tissues. Their related signaling pathways are frequently activated in tumors, and particularly in the rare subpopulation of cancer stem cells. The Wnt signaling pathway is a conserved pathway in animals. Deregulated Wnt signaling has catastrophic consequences for the developing embryo and it is now well appreciated that defective Wnt signaling is a causative factor for a number of pleiotropic human pathologies, including cancer. Hedgehog signaling pathway is linked to tumorigenesis and is aberrantly activated in a variety of cancers. The Notch signaling pathway is a highly conserved cell signaling system present in most animals. It plays an important role in cell-cell communication, and further regulates embryonic development.

MCE designs a unique collection of 358 Wnt/Hedgehog/Notch signaling pathway-related small molecules. Wnt/Hedgehog/Notch Compound Library serves as a useful tool for stem cell research and anti-cancer drug screening.

HY-L017

Stem Cell Signaling Compound Library

1757 compounds

Adult stem cells are important for tissue homeostasis and regeneration due to their ability to self-renew and generate multiple types of differentiated daughters. Self-renewal is reflected by their capacity to undergo multiple/limitless divisions. Several signaling pathways are involved in self-renewal of stem cells, that is, Notch, Wnt, and Hedgehog pathways or Polycomb family proteins. Recent studies mainly focus on cancer stem cell (CSCs), induced pluripotent stem cell (iPSCs), neural stem cell and maintenance of embryonic stem cell pluripotency. Among them, CSCs have been believed to be responsible for tumor initiation, growth, and recurrence that have implications for cancer therapy.

MCE owns a unique collection of 1757 compounds that can be used for stem cell regulatory and signaling pathway research.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-117025A

Manzamine A hydrochloride 1 Publications Verification Keramamine A hydrochloride	Structural Classification Neurological Disease Classification of Application Fields Source classification Marine natural products Pyridine Alkaloids Indole Alkaloids Infection Alkaloids Piperidine Alkaloids Animals Sponge Disease Research Fields	GSK-3 CDK Parasite Proton Pump HSV Autophagy
Manzamine A hydrochloride, an orally active beta-carboline alkaloid, inhibits specifically *GSK-3β* and CDK-5 with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. Manzamine A hydrochloride also shows potent activity against HSV-1 .

HY-N6973

Boldine 1 Publications Verification	Alkaloids Structural Classification Classification of Application Fields Source classification Phenols Polyphenols Plants Lauraceae Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Litsea cubeba (Lour.) Pers.	RANKL/RANK Apoptosis
Boldine is an apomorphine isoquinoline alkaloid extracted from the root of the pheasant pepper (Litsea cubeba). Boldine is an oral effective antioxidant, anti-inflammatory, antitumor agent, and can inhibit osteoclast formation. Boldine induces apoptosis of human bladder cancer cells by regulating ERK, AKT and *GSK-3β. Boldine ameliorates bone destruction by down-regulating the OPG/RANKL/RANK* signaling pathway. It can be used in rheumatoid arthritis research .

HY-N6064

Polygalacin D 1 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Source classification Platycodon grandiflorus (Jacq.) A. DC. Campanulaceae Plants Disease Research Fields Cancer	Apoptosis IAP
Polygalacin D (PGD) is a bioactive compound isolated from Platycodon grandiflorum with anticancer and anti-proliferative properties. PGD suppresses the expression of the IAP family of proteins including survivin, cIAP-1 and cIAP-2 and blocks the PI3K/Akt pathway by inhibiting the phosphorylation of GSK3β, Akt and the expression of PI3K. Polygalacin D induces apoptosis

HY-N3542

Carpachromene	Structural Classification Flavonoids Flavones Source classification Plants Calophyllaceae Calophyllum symingtonianum M.R.Hend. & Wyatt-Sm.	Glucosidase
Carpachromene is a potent α-glucosidase enzyme inhibitor. Carpachromene ameliorates insulin resistance in HepG2 cells via modulating IR/IRS1/PI3k/Akt/GSK3/FoxO1 pathway .

HY-117025

Manzamine A Keramamine A	Infection Alkaloids Structural Classification Neurological Disease Classification of Application Fields Animals Marine natural products Sponge Disease Research Fields Cancer	GSK-3 CDK Parasite Proton Pump HSV Autophagy
Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically *GSK-3β* and CDK-5 with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1 .

HY-N7676

Marein	Cardiovascular Disease Flavonoids Chalcones other families Classification of Application Fields Neurological Disease Source classification Phenols Polyphenols Plants Disease Research Fields	AMPK HDAC
Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC₅₀ of 100 µM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects .

Cat. No.	Product Name	Chemical Structure

HY-10512S

AR-A014418-d3

AR-A014418-d₃ is the deuterium labeled AR-A014418. AR-A014418 is a potent, selective, and ATP-competitive GSK3β inhibitor (IC50=104 nM; Ki=38 nM)[1].

HY-B0712S1

Ceftriaxone-13C2,d3 triethylammonium salt

Ceftriaxone- ¹³C₂,d₃ triethylammonium salt is ¹³C and deuterated labeled Ceftriaxone (HY-B0712). Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC₅₀ value of 0.78 mM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks